

TW402561

L4 ANSWER 1 OF 1 WPIDS COPYRIGHT 2007 THE THOMSON CORP on STN
 AN 1998-086586 [08] WPIDS Full-text
 DNC C1998-029240 [08]
 TI Preparation of solid rapidly disintegrating dosage form with reduced friability - by overfilling mould with aqueous composition, freezing and removing solvent
 DC A96; B03; B07; C02; C07; P33; P71
 IN LAWERENCE J; LAWRENCE J; POSAGE G; POSAGE G W; MAKINO T; MASUDA A; OKADA G
 PA (JAN-C) JANSSEN PHARM NV; (MURA-C) MURATA MFG CO LTD
 CYC 69
 PI WO 9748383 A1 19971224 (199808)* EN 26[11]
 AU 9731757 A 19980107 (199820) EN
 ZA 9705277 A 19990224 (199913) EN 22
 NO 9805876 A 19990216 (199917) NO
 EP 910345 A1 19990428 (199921) EN
 CZ 9804124 A3 19990512 (199925) CS
 SK 9801737 A3 19990611 (199930) SK
 NZ 332832 A 19990729 (199935) EN
 CN 1222075 A 19990707 (199945) ZH
 AU 713062 B 19991125 (200006) EN
 BR 9709829 A 19991116 (200012) PT
 HU 9903654 A2 20000328 (200025) HU
 JP 2000512302 W 20000919 (200050) JA 28
 MX 9810822 A1 19990301 (200051) ES
 KR 2000015849 A 20000315 (200104) KO [11]
 TW 402561 A 20000821 (200117) ZH
 US 6224905 B1 20010501 (200126) EN
 IL 127603 A 20010808 (200157) EN
 EP 910345 B1 20020213 (200212) EN
 DE 69710460 E 20020321 (200227) DE
 ES 2172793 T3 20021001 (200275) ES
 SK 282868 B6 20030109 (200309) SK
 MX 207132 B 20020312 (200363) ES
 CA 2257303 C 20060404 (200625) EN
 CN 1191824 C 20050309 (200634) ZH
 NO 321510 B1 20060515 (200634) NO
 CN 1222075 C 20051005 (200650) ZH
 CZ 297261 B6 20061011 (200668) CS
 ADT WO 9748383 A1 WO 1997-EP3065 19970610; US 6224905 B1 Provisional US 1996-20259P 19960617; AU 9731757 A AU 1997-31757 19970610; AU 713062 B AU 1997-31757 19970610; BR 9709829 A BR 1997-9829 19970610; CA 2257303 C CA 1997-2257303 19970610; CN 1222075 A CN 1997-195603 19970610; CN 1191824 C CN 1997-195603 19970610; DE 69710460 E DE 1997-610460 19970610; EP 910345 A1 EP 1997-927176 19970610; EP 910345 B1 EP 1997-927176 19970610; DE 69710460 E EP 1997-927176 19970610; ES 2172793 T3 EP 1997-927176 19970610; IL 127603 A IL 1997-127603 19970610; NZ 332832 A NZ 1997-332832 19970610; NO 9805876 A WO 1997-EP3065 19970610; EP 910345 A1 WO 1997-EP3065 19970610; CZ 9804124 A3 WO 1997-EP3065 19970610; SK 9801737 A3 WO 1997-EP3065 19970610; NZ 332832 A WO 1997-EP3065 19970610; BR 9709829 A WO 1997-EP3065 19970610; HU 9903654 A2 WO 1997-EP3065 19970610; JP 2000512302 W WO 1997-EP3065 19970610; KR 2000015849 A WO 1997-EP3065 19970610; US 6224905 B1 WO 1997-EP3065 19970610; EP 910345 B1 WO 1997-EP3065 19970610; DE 69710460 E WO 1997-EP3065 19970610; SK 282868 B6 WO 1997-EP3065 19970610; MX 207132 B WO 1997-EP3065 19970610; CA 2257303 C WO 1997-EP3065 19970610; NO 321510 B1 WO 1997-EP3065 19970610; ZA 9705277 A ZA 1997-5277 19970613; TW 402561 A TW 1997-108287 19970616; CZ 9804124 A3 CZ 1998-4124 19970610; JP 2000512302 W JP 1998-502218 19970610; SK 9801737 A3 SK 1998-1737 19970610; SK 282868 B6 SK 1998-1737 19970610; CN 1222075 C CN 1998-119526 19980917; KR 2000015849 A KR 1998-709399 19981120; US 6224905 B1 US 1998-194808 19981203; NO 9805876 A NO 1998-5876 19981215; NO 321510 B1 NO 1998-5876 19981215; MX 9810822 A1 MX 1998-10822 19981216; MX 207132 B MX 1998-10822 19981216; HU 9903654 A2 HU 1999-3654 19970610; CZ 297261 B6 WO 1997-EP3065 19970610; CZ 297261 B6 CZ 1998-4124 19970610
 FDT AU 713062 B Previous Publ AU 9731757 A; DE 69710460 E Based on EP 910345 A; ES 2172793 T3 Based on EP 910345 A; NO 321510 B1 Previous Publ NO 9805876 A; SK 282868 B6 Previous Publ SK 9801737 A; AU 9731757 A Based on WO 9748383 A; EP 910345 A1 Based on WO 9748383 A; CZ 9804124 A3 Based on WO 9748383 A; NZ 332832 A Based on WO 9748383 A; AU

713062 B Based on WO 9748383 A; BR 9709829 A Based on WO
 9748383 A; HU 9903654 A2 Based on WO 9748383 A; JP
 2000512302 W Based on WO 9748383 A; KR 2000015849 A Based on WO
 9748383 A; US 6224905 B1 Based on WO 9748383 A; IL 127603
 A Based on WO 9748383 A; EP 910345 B1 Based on WO 9748383
 A; DE 69710460 E Based on WO 9748383 A; SK 282868 B6 Based
 on WO 9748383 A; CA 2257303 C Based on WO 9748383 A; CZ
 297261 B6 Previous Publ CZ 9804124 A; CZ 297261 B6 Based
 on WO 9748383 A
 PRAI US 1996-20259P 19960617
 WO 1997-EP3065 19970610
 US 1998-194808 19981203
 JP 1997-252205 19970917
 JP 1997-252207 19970917
 IC ICM A61K009-20; B30B011-34; H01P001-32
 IPCI A61J0003-10 [I,A]; A61J0003-10 [I,C]; A61K0031-519 [I,A]; A61K0031-519
 [I,C]; A61K0009-20 [I,A]; A61K0009-20 [I,C]; A61K0009-20 [I,C]
 IPCR A61K0031-445 [I,A]; A61K0031-445 [I,C]; A61K0031-4465 [I,A]; A61K0031-4465
 [I,C]; A61K0031-4468 [I,A]; A61K0031-4468 [I,C]; A61K0009-20 [I,A];
 A61K0009-20 [I,C]; A61K0009-44 [I,A]; A61K0009-44 [I,C]
 AB WO 1997048383 A1 UPAB: 20050704
 Preparation of solid rapidly disintegrating dosage form (SDF) comprising a porous
 network of matrix forming materials (MFM) comprises: (a) overfilling a mould with a
 predetermined amount of aqueous composition comprising MFM so that a convex
 meniscus is created on top of the mould; (b) freezing; and (c) removing the solvent
 by subjecting the product to lyophilisation or to solid state dissolution leaving a
 porous network of MFM. The shape of the bottom surface of the mould is a mirror
 image of the shape of the frozen meniscus on the top, the mirror plane being
 parallel to the plane defined by the rim of the mould, yielding a dosage form
 shaped as a biconvex tablet, having symmetrical top and bottom surfaces. The SDF
 prepared as above is claimed per se. Also claimed is a metal or plastic sheet for
 use in the above process for preparing dosage forms shaped as biconvex tablets
 having symmetrical top and bottom surfaces comprising moulds arranged in a regular
 pattern, the shape of the bottom surface of each mould being a mirror image of the
 shape of a predetermined convex meniscus on the top, the mirror plane being
 parallel to the plane defined by the rim of the mould.
 ADVANTAGE - The solid form disintegrates rapidly and has reduced friability as a
 result of less acute angles between side walls or walls and top or bottom surfaces.
 The symmetry also means that there is no distinction between the top and bottom of
 the dosage form once it is removed from its mould and the biconvex shape can be
 picked up easily and can be arranged to lie on one of the convex surfaces by gently
 shaking. - The shape also serves to distinguish them from prior art dosage forms
 and may assist in preventing errors by physicians, pharmacists and end-users.
 FS CPI: GMPI
 MC CPI: A12-V01; B04-C03B; B11-C09; C04-C03B; C04-C03B; C11-C09; C11-C09